A protein@metal–organic framework nanocomposite for pH-triggered anticancer drug delivery

Abstract

We have synthesized a core@shell nanocomposite using biocompatible bovine serum albumin (BSA) as the core and a pH-sensitive metal-organic framework (MOF) as the shell. Doxorubicin (DOX)/BSA nanoparticles as cores have been prepared. A zeolitic imidazolate framework-8 (ZIF-8) layer has been coated on the outer surface of the DOX/BSA core. The ZIF layer acts as a capsule for the safe storage of DOX under physiological conditions. An efficient pH-responsive drug delivery system using a BSA/DOX@ZIF, in which the drug is not released in PBS at pH 7.4 but is released at low pH (5.0-6.0), has been constructed. Compared to the pure ZIF, a better biocompatibility has been obtained using the BSA/DOX@ZIF. The BSA/DOX@ZIF shows a much higher efficacy than free DOX against the breast cancer cell line MCF-7. The positive charges on the outer surface of the BSA/DOX@ZIF also improve its cellular uptake.

Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of Cancer

“…This PEG-FA/(DOX+VER)@ZIF-8 released faster and more at pH 5.0 than at physiological conditions. Furthermore, Liang et al encapsulated doxorubicin and bovine serum albumin with ZIF-8, which also could be kept under physiological conditions and released under tumor conditions [63]. Tang et al synthesizes a nanocapsule using the pH sensitivity of ZIF-8 [64].…”

Redox-active, luminescent coordination nanosheet capsules containing magnetite

“…Films can be directly synthesized by a reaction at the liquid-liquid or gas-liquid interface, where metal ions and organic ligands exist in different phases. Most previous work on CONASHs has used planar interfaces to obtain planar films; however, other spherical functional nanomaterials have been extensively studied [19][20][21][22][23][24][25][26][27][28][29][30][31] .…”

Recent Trends in Covalent and Metal Organic Frameworks for Biomedical Applications

“…Hybrid MOFs have begun to appear in drug delivery contexts. Liang [ 96 ] produced a core-shell protein@ZIF entity that released DOX at low pH, similar in concept to the pH—triggered drug release investigated by Rengaraj [ 24 ] and Tian [ 65 ]. This protein@ZIF hybrid, effective against breast cancer (MCF-7) in vitro, consisted of a DOX/Bovine Serum Albumin (BSA) core surrounded by a ZIF-8 shell.…”

“…This protein@ZIF hybrid, effective against breast cancer (MCF-7) in vitro, consisted of a DOX/Bovine Serum Albumin (BSA) core surrounded by a ZIF-8 shell. In environments with low pH (5.0–6.0), dissociation of the ZIF was triggered, promoting drug release [ 96 ]. Impressively, this hybrid showed crystallinity, effectively no leaching of drug, and better biocompatibility than bare ZIF-8.…”

“…Abraxane is an oil-water emulsion designed to deliver paclitaxel, a chemotherapeutic agent [ 5 ]. This was the first nanomedicine FDA-approved for metastatic breast cancer [ 96 ].…”